Skip to main content
Funded Studies

Leo Verhagen-Metman, PhD

Associate Professor of Neurological Sciences at Rush Medical College, Rush University Medical Center

Leo Verhagen Metman, MD, PhD, is a board-certified neurologist, an Associate Professor at Rush Medical College, and the Medical Director of the Neurosurgery Program for Movement Disorders, at Rush University Medical Center, Chicago, Illinois. He specializes in the medical and surgical management of patients with Parkinson's disease and other Movement Disorders such as Essential Tremor and Dystonia. Dr. Verhagen earned his medical and doctorate degrees from the University of Leiden in the Netherlands in 1983. After coming to the United States in 1985 to work in the Division of Artificial Organs at the University of Utah, he decided to pursue his interest in the neurosciences and accepted a fellowship in the Division of Restorative Neurology and Human Neurobiology at Baylor College of Medicine in Texas. Subsequently, he completed a neurology residency at Thomas Jefferson University Hospital in Philadelphia. Upon completion in 1992, he accepted a fellowship at the National Institutes of Health in the Experimental Therapeutics Branch of the National Institute of Neurological Disorders and Stroke. After completing this fellowship in 1994, he stayed at the NIH for another 5 years, first as Visiting Associate, later as Visiting Scientist. The Branch's main focus was on pharmacological studies of motor response complications in Parkinson's disease. In 1999 he joined the Movement Disorder Section of the Department of Neurological Sciences at Rush University Medical center, one of the largest movement disorders centers in the United States, to work with his colleagues on better treatments for PD and other movement disorders through clinical research.

Associated Grants

  • Treating speech disorders in patients with Parkinson's disease using altered auditory feedback


We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.